trending Market Intelligence /marketintelligence/en/news-insights/trending/xvrabgcu1exy_hmlve54qq2 content esgSubNav
In This List

Tenax Therapeutics granted more time to regain Nasdaq compliance

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Tenax Therapeutics granted more time to regain Nasdaq compliance

Tenax Therapeutics Inc. was granted an extra 180 days, or until March 12, 2018, to regain compliance with Nasdaq's minimum bid price requirement.

The Morrisville, N.C.-based specialty pharmaceutical company had received a notice from the exchange March 17, stating that it was not in compliance with the minimum bid price requirements for continued listing on the Nasdaq Capital Market.

The company had until Sept. 11 to regain the compliance but was unable to do so.

To regain compliance before March 12, the bid price for Tenax's common stock must close at $1 per share or more for at least 10 consecutive business days.